Richard Rupp, MD

Projects

Projects per year 2007 2017 2018 2027

• 32 Active
• 94 Completed

Projects per year

Search results

• Completed

  IMPAACT Leadership Group-PTCL 03

  Rupp, R.

  12/1/20 → 11/30/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU)

  Rupp, R.

  3/13/20 → 11/30/20

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU)

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  3/13/20 → 11/30/20

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  Mapp Biopharmaceutical Inc

  6/27/19 → 6/30/21

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  6/27/19 → 6/30/21

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  6/27/19 → 6/30/21

  Project: Other project

• Zmapp Expanded Access Protocol, The University of Texas Medical Branch (UTMB)

  Rupp, R.

  6/27/19 → 6/30/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 -dose Regimen of V114 in Healthy Infants (PNEU-PED)

  Rupp, R.

  4/25/19 → 4/24/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13¿ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

  Rupp, R.

  9/14/18 → 9/13/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13¿ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

  Rupp, R.

  9/14/18 → 9/13/21

  Project: Other project

• Comprehensive Analysis of CMV-specific T cells in Human Subjects Receiving a Replication-defective Human Cytomegalovirus Vaccine

  Rupp, R.

  8/28/18 → 8/27/21

  Project: Other project

• A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Administered Concomitantly with Routine Vaccines to Heal

  Rupp, R.

  7/9/18 → 7/8/20

  Project: Other project

• A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Administered Concomitantly with Routine Vaccines to Heal

  Rupp, R.

  7/9/18 → 7/8/20

  Project: Other project

• A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R.

  7/5/18 → 7/4/21

  Project: Other project

• A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

  Rupp, R.

  7/2/18 → 7/1/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y

  Rupp, R.

  7/1/18 → 6/30/21

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 One Year Later in Healthy Adults 50 Years of Age or Older (PN

  Rupp, R.

  6/11/18 → 6/10/21

  Project: Other project

• A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when administered concomitantly with routine pe

  Rupp, R.

  5/2/18 → 5/1/21

  Project: Other project

• An Expanded Access Treatment Protocol for Zmapp TM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

  Rupp, R.

  5/1/18 → 6/26/19

  Project: Other project

• An Expanded Access Treatment Protocol for Zmapp TM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

  Rupp, R.

  5/1/18 → 6/26/19

  Project: Other project

• Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35

  Rupp, R.

  4/24/18 → 4/23/21

  Project: Other project

• A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R.

  3/30/18 → 3/29/21

  Project: Other project

• A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R.

  3/30/18 → 3/29/21

  Project: Other project

• Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

  Rupp, R.

  2/5/18 → 12/31/20

  Project: Other project

• Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

  Rupp, R.

  2/5/18 → 12/31/19

  Project: Other project

• Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

  Rupp, R.

  2/5/18 → 12/31/19

  Project: Other project

• Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

  Rupp, R.

  2/5/18 → 12/31/20

  Project: Other project

• A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Live-Attenuated Tetravalent Dengue Vaccine (V181) in Flavivirus-Naive and Flavivirus-Experienced Health Adults (MK-V181-001-01)

  Rupp, R.

  1/4/18 → 1/3/21

  Project: Other project

• A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Live-Attenuated Tetravalent Dengue Vaccine (V181) in Flavivirus-Naive and Flavivirus-Experienced Health Adults (MK-V181-001-01)

  Rupp, R.

  1/4/18 → 1/3/21

  Project: Other project

• IMPAACT 2021 startup

  Rupp, R.

  1/1/18 → 11/30/20

  Project: Other project

• IMPAACT 2021 startup

  Rupp, R.

  Johns Hopkins University

  1/1/18 → 11/30/20

  Project: Other project

• IMPAACT 2021 startup

  Rupp, R.

  1/1/18 → 11/30/20

  Project: Other project

• IMPAACT 2021 startup

  Rupp, R.

  1/1/18 → 11/30/20

  Project: Other project

• A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

  Rupp, R.

  8/21/17 → 8/20/19

  Project: Other project

• A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

  Rupp, R.

  8/21/17 → 8/20/19

  Project: Other project

• lmmunogenicity, reactogenicityan safetystudyof Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

  Rupp, R.

  8/18/17 → 8/17/19

  Project: Other project

• lmmunogenicity, reactogenicityan safetystudyof Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

  Rupp, R.

  8/18/17 → 8/17/19

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  7/28/17 → 2/28/21

  Project: Other project

• Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

  Rupp, R.

  7/28/17 → 2/28/21

  Project: Other project

• A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13¿ in Healthy Infants

  Rupp, R.

  2/8/17 → 2/7/21

  Project: Other project

• A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13¿ in Healthy Infants

  Rupp, R.

  2/8/17 → 2/7/21

  Project: Other project

• A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDEDS TUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER

  Rupp, R.

  2/7/17 → 2/6/22

  Project: Other project